ARMATA PHARMACEUTICALS, INC. Proceeds from Issuance of Secured Debt
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Proceeds from Issuance of Secured Debt of $25.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance of secured debt for the quarter ending 2025-12-31 was $0.00.
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance of secured debt for the quarter ending 2025-09-30 was $15.00M.
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance of secured debt for the quarter ending 2025-06-30 was $0.00.
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance of secured debt for the quarter ending 2025-03-31 was $10.00M, a 71.34% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2025 was $25.00M, a 28.34% decline from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2024 was $34.89M, a 39.98% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2023 was $24.93M.
| Period end | Proceeds from Issuance of Secured Debt 3 month | Proceeds from Issuance of Secured Debt 6 month | Proceeds from Issuance of Secured Debt 9 month | Proceeds from Issuance of Secured Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.00M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $15.00M derived: sum of 2 quarters · filed 2026-03-25 | $15.00M derived: sum of 3 quarters · filed 2026-08-12 | $25.00M 10-K · filed 2026-03-25 |
| 2025-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $15.00M derived: sum of 2 quarters · filed 2026-08-12 | $25.00M 10-Q · filed 2025-11-12 | $25.00M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $10.00M 10-Q · filed 2026-08-12 | $10.00M derived: sum of 3 quarters · filed 2026-08-12 | $10.00M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $10.00M 10-Q · filed 2026-05-13 | $10.00M derived: sum of 2 quarters · filed 2026-05-13 | $10.00M derived: sum of 3 quarters · filed 2026-05-13 | $10.00M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $34.89M 10-K · filed 2026-03-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $34.89M 10-Q · filed 2025-11-12 | $34.89M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $34.89M 10-Q · filed 2025-08-12 | $34.89M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $34.89M 10-Q · filed 2025-05-14 | $34.89M derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $24.93M 10-K · filed 2025-03-21 | ||
| 2023-09-30 | $24.93M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |